- Previous Close
34.05 - Open
34.01 - Bid 33.87 x 4000
- Ask 34.49 x 3200
- Day's Range
33.95 - 34.31 - 52 Week Range
31.72 - 45.93 - Volume
3,165,798 - Avg. Volume
5,392,845 - Market Cap (intraday)
69.92B - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
22.85 - EPS (TTM)
1.50 - Earnings Date Feb 5, 2025
- Forward Dividend & Yield 1.56 (4.55%)
- Ex-Dividend Date Nov 15, 2024
- 1y Target Est
44.22
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
www.gsk.com70,212
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent News: GSK
View More
Performance Overview: GSK
Trailing total returns as of 2025-01-24, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GSK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GSK
View MoreValuation Measures
Market Cap
68.37B
Enterprise Value
84.23B
Trailing P/E
22.86
Forward P/E
8.03
PEG Ratio (5yr expected)
0.79
Price/Sales (ttm)
1.83
Price/Book (mrq)
4.04
Enterprise Value/Revenue
2.18
Enterprise Value/EBITDA
10.17
Financial Highlights
Profitability and Income Statement
Profit Margin
8.02%
Return on Assets (ttm)
7.24%
Return on Equity (ttm)
21.85%
Revenue (ttm)
31.31B
Net Income Avi to Common (ttm)
2.51B
Diluted EPS (ttm)
1.50
Balance Sheet and Cash Flow
Total Cash (mrq)
3.21B
Total Debt/Equity (mrq)
119.37%
Levered Free Cash Flow (ttm)
6.04B
Research Analysis: GSK
View MoreCompany Insights: GSK
GSK does not have Company Insights
Research Reports: GSK
View MoreMore Trump Healthcare Nominations Largely Aligned With Kennedy
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
RatingPrice TargetTrump’s Nomination of RFK Jr. to Lead HHS a Potential Industry Headwind
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
RatingPrice TargetDiscounted price offers buying opportunity
GSK plc, based in Brentford, UK, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical products. The company's leading products include treatments for asthma and COPD; products for HIV infection; and a range of vaccines. The company has active research and development programs in immuno-inflammation, neuroscience, metabolic pathways, ophthalmology, respiratory and infectious diseases, and biopharmaceuticals.
RatingPrice TargetStocks are higher Friday morning, and appear set to end a very positive week
Stocks are higher Friday morning, and appear set to end a very positive week with some additional gains. A catalyst today is consumer-sentiment data from the University of Michigan that suggests consumer confidence is on the upswing. As of this writing, the Dow Jones Industrial Average and the S&P 500 are clearly in the green, while the Nasdaq Composite is flipping back and forth from slightly green to slightly red. But as that index has popped by almost 6% this week alone, it is hard to complain about today's action.